Holen Sie sich die Stockscreener-App
14.24
6.38%
-0.97
Vorhandelsmarkt:
14.30
0.06
+0.42%
Schlusskurs vom Vortag:
$15.21
Offen:
$15.13
24-Stunden-Volumen:
466.32K
Relative Volume:
1.62
Marktkapitalisierung:
$365.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$11.77M
KGV:
24.62
EPS:
0.5785
Netto-Cashflow:
$-19.23M
1W Leistung:
-16.82%
1M Leistung:
+8.79%
6M Leistung:
-45.71%
1J Leistung:
-39.51%
1-Tages-Spanne:
$14.19
$15.18
1-Wochen-Bereich:
$14.19
$17.36
52-Wochen-Spanne:
$11.87
$29.79
Tourmaline Bio Inc Stock (TRML) Company Profile
Firmenname
Tourmaline Bio Inc
Sektor
Branche
Telefon
646-481-9832
Adresse
27 WEST 24TH STREET, NEW YORK
Vergleichen Sie TRML mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
14.24 | 365.76M | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-06 | Eingeleitet | Wedbush | Outperform |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-11-11 | Bestätigt | H.C. Wainwright | Buy |
| 2023-12-15 | Eingeleitet | Jefferies | Buy |
| 2023-12-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-11-17 | Eingeleitet | Truist | Buy |
| 2023-10-31 | Eingeleitet | Guggenheim | Buy |
| 2023-10-25 | Eingeleitet | Piper Sandler | Overweight |
| 2022-10-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
Alle ansehen
Tourmaline Bio Inc Aktie (TRML) Neueste Nachrichten
Swiss National Bank Takes Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Leading Factor Driving the Thyroid Eye Disease (TED) Market in 2025: Thyroid Disorders And Their Influence ... - WhaTech
ProfittoPath - TradingView
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Sold by AlphaQuest LLC - Defense World
Tourmaline Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Alumis Inc. (NASDAQ:ALMS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Tourmaline Bio (NASDAQ:TRML) Stock Price Expected to Rise, Wedbush Analyst Says - Defense World
HC Wainwright Raises Tourmaline Bio (NASDAQ:TRML) Price Target to $50.00 - Defense World
H.C. Wainwright raises Tourmaline Bio stock target to $50 By Investing.com - Investing.com Canada
Tourmaline Bio price target raised to $43 from $42 at Wedbush - TipRanks
H.C. Wainwright raises Tourmaline Bio stock target to $50 - Investing.com India
Wedbush Lifts Price Target on Tourmaline Bio to $43 From $42, Keeps Outperform Rating - Marketscreener.com
Tourmaline Bio shares fall as Q4 loss widens By Investing.com - Investing.com Australia
Tourmaline Bio’s 2024 Financial Results and Strategic Advances - TipRanks
Tourmaline Bio shares fall as Q4 loss widens - Investing.com
TOURMALINE BIO Earnings Results: $TRML Reports Quarterly Earnings - Nasdaq
Tourmaline Bio, Inc. SEC 10-K Report - TradingView
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Tourmaline Bio's cash position to provide cash runway into second half of 2027 -March 13, 2025 at 07:39 am EDT - Marketscreener.com
Tourmaline Bio, Inc. Announces Over-Enrolled Phase 2 TRANQUILITY Trial and Strengthens Cardiovascular Scientific Advisory Board Amid Positive Financial Outlook - Nasdaq
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business - Bluefield Daily Telegraph
Tourmaline Bio Secures 2.5-Year Cash Runway with $294M, Accelerates Key Clinical Trials - StockTitan
Tourmaline Bio (TRML) Projected to Post Earnings on Tuesday - Defense World
Wedbush Forecasts Tourmaline Bio FY2024 Earnings - Defense World
Tourmaline Bio (NASDAQ:TRML) Research Coverage Started at Wedbush - Defense World
Rhumbline Advisers Has $722,000 Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio rises as Wedbush initiates with Outperform - MSN
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - NewsBreak
Wedbush bullish on Tourmaline Bio, initiates with an Outperform - TipRanks
Wedbush Initiates Coverage on Tourmaline Bio With Outperform Rating, $42 Price Target - Marketscreener.com
Wedbush Initiates Tourmaline Bio at Outperform With $42 Price Target -March 06, 2025 at 07:22 am EST - Marketscreener.com
Robinhood initiated, MongoDB downgraded: Wall Street's top analyst calls - Yahoo Finance
We Tested Over 25 Curling Irons. These 13 Are the Best - MarieClaire.com
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025 - The Manila Times
Volatus Aerospace and Draganfly Expand Collaboration to Service High-Value Geospatial Power Utility Customers - The Manila Times
3 Reasons to Buy American Express Stock Like There's No Tomorrow - The Globe and Mail
When and Where to Catch Tourmaline Bio's Next Investor Presentation - StockTitan
Brokers Set Expectations for Tourmaline Bio FY2024 Earnings - MarketBeat
Truist maintains $74 target on Tourmaline Bio stock, reiterates buy By Investing.com - Investing.com UK
Lifesci Capital Predicts Tourmaline Bio FY2024 Earnings - Defense World
Financial Survey: X4 Pharmaceuticals (NASDAQ:XFOR) & Tourmaline Bio (NASDAQ:TRML) - Defense World
Lifesci Capital Initiates Coverage on Tourmaline Bio (NASDAQ:TRML) - Armenian Reporter
Tourmaline Bio (NASDAQ:TRML) Coverage Initiated by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Tourmaline Bio (TRML) with Outperform Recommendation - MSN
Talaris Therapeutics stock hits 52-week low at $12.06 By Investing.com - Investing.com Australia
Talaris Therapeutics stock hits 52-week low at $12.06 - Investing.com
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Vaxcyte (NASDAQ:PCVX) & Tourmaline Bio (NASDAQ:TRML) Financial Review - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $54.00 Average PT from Brokerages - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Finanzdaten der Tourmaline Bio Inc-Aktie (TRML)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tourmaline Bio Inc-Aktie (TRML) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kulkarni Sandeep Chidambar | CEO |
Aug 16 '24 |
Buy |
13.79 |
5,221 |
71,998 |
5,221 |
3.89%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):